Laboratory and Genetic Testing for Use of 5-Fluorouracil in Patients With Cancer
Under this BCBS policy, assay testing for 5-fluorouracil area under the curve to adjust 5-fluorouracil dose for individuals with cancer is considered investigational. Genetic testing for DPYD or TYMS variants to guide 5-fluorouracil dosing or treatment choice in individuals with cancer is also considered investigational. The policy history records 04/17/2025 and 04/18/2024 reviews with no changes.